Xylem (XYL) Tops Q1 EPS by 8c, provides guidance

Xylem (NYSE: XYL) reported Q1 EPS of $1.03, $0.08 better than the analyst estimate of $0.95. Revenue for the quarter came in at $2.1 billion versus the consensus estimate of $2.04 billion.

GUIDANCE:

Xylem sees FY 2025 EPS of $4.50-$4.70, versus the consensus of $4.63. Xylem sees FY 2025 revenue of $8.7-8.8 billion, versus the consensus of $8.736 billion.

For earnings history and earnings-related data on Xylem (XYL) click here.

You May Also Be Interested In

• Reddit to join S&P 500 index on Aug. 18, shares leap
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c